Editor in Chief
Thomas Abrams, MD, is an Assistant Professor of Medicine at Harvard Medical School, a Senior Physician at Dana-Farber Cancer Institute, and the Director of the Liver Cancer Task Force of the Harvard Cancer Center. He specializes in the treatment of patients with gastrointestinal cancers, including pancreatic, gastric, colorectal, esophageal, gallbladder, and primary liver cancers. Dr. Abrams’ primary research interest is the early detection of liver cancers through the discovery and application of novel biomarkers. He has authored or coauthored numerous publications in peer-reviewed journals.
Sara Hurvitz, MD, is a Professor of Medicine in the Division of Hematology/Oncology and the Director of the Breast Cancer Clinical Research Program at the University of California Los Angeles (UCLA) David Geffen School of Medicine. She is also Co-Director of the Santa Monica–UCLA Outpatient Hematology/Oncology Practices and Medical Director of the Jonsson Comprehensive Cancer Center Clinical Research Unit. Dr. Hurvitz specializes in the treatment of patients with breast cancer. She has designed, implemented, and led national and international trials evaluating novel treatments for this disease.
Ulka Vaishampayan, MD, is a Professor of Internal Medicine and the Director of the Phase 1 Program at the University of Michigan Rogel Cancer Center. She is also the Chair of the SWOG Advanced Renal Committee, a member of the National Cancer Institute (NCI) Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology. Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma, and her research focuses on translational drug development. She has authored or coauthored numerous publications in peer-reviewed journals.
Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN®, is a nurse practitioner at Memorial Sloan Kettering Cancer Center (MSKCC), where he specializes in the treatment of patients with breast cancer. He is also the lead clinician for MSKCC’s scalp cooling program, which seeks to minimize chemotherapy-induced hair loss. Mr. Ross has authored or coauthored numerous publications focused on oral therapy adherence and symptom management to optimize outcomes in patients with breast cancer. He has won several awards, including the Oncology Nursing Certification Corporation (ONCC) Certified Breast Care Nurse of the Year.
Maria Badillo, MSN, RN, OCN®, CCRP, is the Research Nurse Manager in the Mantle Cell Lymphoma/Myeloma Department at The University of Texas MD Anderson Cancer Center. As a clinical trial manager, she develops research strategies and programs, manages protocol design and implementation, and coordinates patient participation in phase 1, 2, and 3 clinical trials. Ms. Badillo has been a speaker at several conferences, including the Oncology Nursing Society Congress and the Academy of Oncology Nurse and Patient Navigators Conference. Her research focuses on the development of novel therapeutics for patients with hematologic malignancies and the management of adverse events to optimize treatment outcomes.
Richard F. Riedel, MD, is an Associate Professor in the Division of Medical Oncology at Duke University Medical Center. Additionally, he serves as the Associate Director of Clinical and Translational Research for the Duke Sarcoma Program and is a member of the Duke Cancer Institute. His clinical practice is dedicated to the care of patients with bone and soft tissue sarcoma, and his research interests lie in identifying novel therapies for these patients. Dr. Riedel is a nationally recognized expert in the field of soft tissue and bone sarcoma and is active at the national level in preparing national sarcoma guidelines (NCCN Soft Tissue Sarcoma Guidelines panel member and NCCN GIST Guidelines panel member) and educational initiatives. He has authored or coauthored numerous peer-reviewed publications focused on improving outcomes for patients with sarcoma.
Beth Sandy, MSN, CRNP, is an Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center in Philadelphia, Pennsylvania. She specializes in the treatment and supportive care of patients with lung cancer and other thoracic malignancies. Ms. Sandy has authored or coauthored numerous peer-reviewed publications, posters, and book chapters, and has been a speaker at several national and international conferences. She is a member of several professional societies and is active on committees and editorial boards for APSHO, IASLC, MASCC, ONS, and SITC.
Richard D. Carvajal, MD, is an Associate Professor of Medicine at Columbia University Irving Medical Center, where he serves as both Director of Experimental Therapeutics and Director of the Melanoma Service within the Division of Hematology/Oncology. He also serves as Co-Leader of the Precision Oncology and Systems Biology Program within the Herbert Irving Comprehensive Cancer Center. Dr. Carvajal’s research is focused on the development of novel therapies for patients with melanoma and other cancers, including uncommon clinical and molecular subsets such as those arising from the eye (uveal melanomas), mucosal surfaces of the body (mucosal melanomas), and palms of the hands, soles of the feet, or under the fingernails (acral melanomas). He has been the principal or co-investigator of over 500 clinical trials and has authored or coauthored over 200 peer-reviewed manuscripts, books, and book chapters. In addition, Dr. Carvajal serves as Co-Chair of the International Rare Cancer Initiative Uveal Melanoma working group, a joint initiative between the National Cancer Institute, the European Organization for Research and Treatment of Cancer, and the Cancer Research UK to enhance international collaboration in clinical trials for uveal melanoma.
Rahul Banerjee, MD, FACP, is an Assistant Professor in the Division of Medical Oncology at the University of Washington (Seattle, WA); he also holds a faculty appointment at the Fred Hutchinson Cancer Center. He previously completed his Hematology/Oncology Fellowship and Advanced BMT/CAR-T Fellowship at the University of California, San Francisco. His clinical interests are in multiple myeloma, AL amyloidosis, and CAR-T therapy. His research interests are in toxicity management, digital health, and the patient experience.
Lei Zhao, MD, PhD, is an Assistant Professor of Pathology at Brigham and Women’s Hospital in Boston, Massachusetts. Her clinical interests focus on cancer genetics, metabolic syndrome, and gastrointestinal, liver, and surgical pathology. Dr. Zhao has published numerous peer-reviewed articles centered on improving outcomes of patients with gastrointestinal diseases.